Article Text

other Versions

PDF
Breast cancer susceptibility variants alter risks in familial disease
  1. Ayse Latif (ayshe.latif{at}postgrad.manchester.ac.uk)
  1. University of Manchester, United Kingdom
    1. Kristen D Hadfield (kristen.hadfield{at}manchester.ac.uk)
    1. University of Manchester, United Kingdom
      1. Stephen A Roberts (steve.roberts{at}manchester.ac.uk)
      1. University of Manchester, United Kingdom
        1. Andrew Shenton
        1. St Mary's Hospital, United Kingdom
          1. Fiona Lalloo (fiona.lalloo{at}cmft.nhs.uk)
          1. St Mary's Hospital, United Kingdom
            1. Graeme C M Black (graeme.black{at}manchester.ac.uk)
            1. University of Manchester, United Kingdom
              1. Anthony Howell (anthony.howell{at}christie.nhs.uk)
              1. Whythenshawe Hospital, United Kingdom
                1. D Gareth Evans (gareth.evans{at}cmft.nhs.uk)
                1. St Mary's Hospital, United Kingdom
                  1. William G Newman (william.newman{at}cmft.nhs.uk)
                  1. University of Manchester, United Kingdom

                    Abstract

                    Background: Recent candidate and genome wide association studies have identified variants altering susceptibility to breast cancer. We aimed to establish the relevance of these variants to breast cancer risk in familial breast cancer cases both with and without BRCA1 or BRCA2 (BRCA1/2) mutations.

                    Methods: A cohort of unrelated individuals affected from breast cancer due to the presence of either BRCA1 (121) or BRCA2 mutations (109) and females with familial breast cancer, not due to BRCA1/2 mutations (722) were genotyped using Taqman SNP Genotyping Assays. Allele frequencies were compared with an ethnically and gender-matched group (436).

                    Results: A synonymous variant (Ser51) in TOX3 (previously TNRC9) was associated with an increased risk of breast cancer (OR=p<0.001) in BRCA2 mutation carriers. We replicated the associations for FGFR2 (p=0.046), TOX3 (p<0.001), MAP3K1 (p=0.03), CASP8 (p=0.02) and the chromosome 8-associated SNP (p=0.004) in individuals without BRCA1/2 mutations. Additionally, homozygote carriers of MAP3K1 variants were shown to have a significantly lower Manchester Score (p=0.003), while individuals carrying one or two copies of the FGFR2 variant had a higher Manchester Score (p=0.01).

                    Conclusion: Our study confirms that susceptibility variants in FGFR2, TOX3, MAP3K1, and on chromosome 8q are all associated with increased risk of cancer in individuals with a family history of breast cancer, whereas CASP8 is protective in this context. The level of risk is dependent upon the strength of the family history and the presence of a BRCA1/2 mutation and contributes to the understanding of the use of these variants in clinical risk prediction.

                    Statistics from Altmetric.com

                    • Web Only Data 47/2/126

                      Request permissions

                      If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.